Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Antipsychotic drugs : pharmacodynamics and pharmacokinetics : proceedings of the international symposium held in Wenner-Gren Center, Stockholm, september 1974 / edited by G. Sedvall, B. Uvnas, Y. Zotterman
| Antipsychotic drugs : pharmacodynamics and pharmacokinetics : proceedings of the international symposium held in Wenner-Gren Center, Stockholm, september 1974 / edited by G. Sedvall, B. Uvnas, Y. Zotterman |
| Pubbl/distr/stampa | Oxford [etc.] : Pergamon Press, 1976 |
| Descrizione fisica | XII, 462 p. : ill. ; 24 cm |
| Disciplina | 615.788 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-990002035440203316 |
| Oxford [etc.] : Pergamon Press, 1976 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Chimica per l'anima : psicofarmaci e terapie alternative / Josef Zehentbauer
| Chimica per l'anima : psicofarmaci e terapie alternative / Josef Zehentbauer |
| Autore | Zehentbauer, Josef |
| Pubbl/distr/stampa | Diegaro di Cesena : Macro, 2002 |
| Descrizione fisica | 395 p. : ill. ; 24 cm |
| Disciplina | 615.788 |
| Soggetto topico |
Psychotropic Drugs - Pharmacokinetics
Psychopharmacology - Methods |
| ISBN | 9788875073732 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | ita |
| Record Nr. | UNISALENTO-991002473369707536 |
Zehentbauer, Josef
|
||
| Diegaro di Cesena : Macro, 2002 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. del Salento | ||
| ||
CNS drugs
| CNS drugs |
| Pubbl/distr/stampa | Mairangi Bay, Auckland, N.Z., : Adis International, 1994- |
| Disciplina | 615.788 |
| Soggetto topico |
Neuropsychopharmacology
Central Nervous System Diseases - drug therapy Mental Disorders - drug therapy Nervous System Diseases - drug therapy Psychotropic Drugs - therapeutic use Neuropsychopharmacologie |
| Soggetto genere / forma | Periodical |
| Soggetto non controllato | Humans - Nervous system - Drug therapy |
| ISSN | 1179-1934 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996336155103316 |
| Mairangi Bay, Auckland, N.Z., : Adis International, 1994- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
CNS drugs
| CNS drugs |
| Pubbl/distr/stampa | Mairangi Bay, Auckland, N.Z., : Adis International, 1994- |
| Disciplina | 615.788 |
| Soggetto topico |
Neuropsychopharmacology
Central Nervous System Diseases - drug therapy Mental Disorders - drug therapy Nervous System Diseases - drug therapy Psychotropic Drugs - therapeutic use Neuropsychopharmacologie |
| Soggetto genere / forma | Periodical |
| Soggetto non controllato | Humans - Nervous system - Drug therapy |
| ISSN | 1179-1934 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910481984103321 |
| Mairangi Bay, Auckland, N.Z., : Adis International, 1994- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drugs and human behavior : biopsychosocial aspects of psychotropic substances use / / Denise De Micheli [and four others]
| Drugs and human behavior : biopsychosocial aspects of psychotropic substances use / / Denise De Micheli [and four others] |
| Autore | De Micheli Denise |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (564 pages) |
| Disciplina | 615.788 |
| Soggetto topico |
Psychotropic drugs - Physiological effect
Drugs of abuse - Physiological effect Drug abuse - Psychological aspects Drogoaddicció Aspectes psicològics |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-62855-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- Contributors -- Part I: Introductory Aspects and Main Concepts -- Chapter 1: Humanity and the Use of Substances: A Historical Overview -- Introduction -- Timelines as a Way of Reading History -- Drugs: Concepts and Prejudices -- Before Civilizations: The Prehistoric Drug Registries -- Greek Civilization -- Elleusis -- Romans and Christianity -- Christianity and Witch Hunt -- Criminalization and Stigma of Substance Use -- Meanwhile, in Islam.. -- Middle Ages and Modern Ages: Money and Power on the Agenda -- New World, Old Problems -- XIX and XX Centuries: Isolated Active Principles -- Prohibitionism -- Reflecting from.. -- References -- Chapter 2: Drug Use and Substance Use Disorders in Brazil and the World: Epidemiological Data -- Introduction -- What Is Epidemiology? -- Challenges of Epidemiological Drug Research -- Current Scenario on Drug Use -- Historical Overview -- Alcohol -- Tobacco -- Other Drugs -- Marijuana -- Cocaine, Crack, and Similar Drugs -- Non-prescribed Use of Drugs -- Drug Use Consequences -- Final Considerations -- References -- Chapter 3: Anthropological Studies in Drug Use Contexts: An Introduction to Theoretical, Methodological, and Ethical Aspects -- Introduction -- Historical Overview -- Current Surveys -- Ethical and Methodological Aspects of Ethnographic Research with Drug Dealers Users -- References -- Chapter 4: Neuroanthropology of Drugs: Relations Between the Brain, Social Context, and Use of Psychoactive Substances -- Introduction -- Drugs: Definitions, Classifications, and Neurobiological Aspects -- Use and Dependence on Substances: A Historical-Anthropological View -- Biopsychosocial Models: Perspectives on Drug Use and Dependence -- Neuroanthropology: Reflections and Conceptual Applications -- Final Considerations -- References.
Chapter 5: Substance Use Among Older Adults: Epidemiological Aspects, Associated Variables, and Organic Risks -- Introduction: Aging in Brazil and the World -- Older Adult and Substance Use -- Physical, Social, and Psychological Differences -- Epidemiology of Drug Use Among Older Adult People -- Alcohol -- Tobacco -- Illicit Drugs -- Medicines -- Sorting and Evaluation Instruments -- Diagnosis -- Types of Treatment and Other Interventions -- Final Considerations -- References -- Part II: Biological Aspects -- Chapter 6: Genetic Aspects of Substance Use Disorders -- Introduction: Substances of Abuse -- Alcohol as an Example of Drug Abuse -- Genetic Aspects of Substance Use Disorders -- References -- Chapter 7: Neuroscience, Epigenetics, and Psychotropic Substances -- Introduction -- Neurobiology of Drugs of Abuse -- Epigenetics and Drugs of Abuse -- Changes in Histone Acetylation and Methylation -- Final Considerations -- References -- Chapter 8: Pharmacology of Drugs of Abuse: Pharmacokinetics and Pharmacodynamics of Psychotropic Compounds -- Introduction: Drugs of Abuse, Dopamine, and the Reward System -- History of Psychotropic Drug Use -- General Aspects of Pharmacodynamics of Drugs of Abuse -- The Importance of Pharmacokinetics in Drug Abuse -- Current and Selected Topics on Drugs -- Medicinal Properties and Risks of Cannabis -- Animal Studies: The Cannabinoid Tetrad -- Effects of Cannabis and Its Medicinal Interest -- Unpleasant Effects of Cannabis -- Use of Marijuana During Adolescence and the Risk of Schizophrenia -- Alcohol, Endorphins, and Endocannabinoids: What is the Relationship? -- The "Flavors of Nicotine" -- Final Considerations -- References -- Chapter 9: Impacts of Drug (Ab)Use on the Development of the Human Central Nervous System -- Introduction -- Neurobiology of Drug Use -- Ventral Tegmental Area (VTA). Nucleus Accumbens (Nacc) and Mesolimbic Pathway -- Prefrontal Cortex (PFC) and Mesocortical Path -- Brain Reward System and the Development of Drug Dependence -- Brain Development and Maturation -- Myelinization and Synaptic Pruning -- Maturation Directionality (Posterior-Anterior and Subcortical-Cortical) -- Impact of Drug Use on Development and Maturation of the CNS -- Prenatal Drug Exposure -- Fetal Alcoholic Syndrome -- Drug Use during Adolescence -- Final Considerations -- References -- Chapter 10: Effects of Substance Use on Neural Development -- Introduction -- Psychoactive Drugs and the Neurodevelopment -- Final Considerations -- References -- Chapter 11: Neuropsychological and Behavioral Aspects of Drug Use and Abuse: Theory, Research, and Intervention -- Introduction -- Neuropsychological Aspects of Psychotropic Drugs -- Alcohol -- Cocaine/Crack -- Marijuana -- Explanatory Theoretical Models on SUD -- Clinical Interventions for SUD Treatment -- Final Considerations -- References -- Part III: Psychological Aspects -- Chapter 12: Psychological Evaluation in Users of Psychoactive Substances: The Psychodiagnosis Process -- Introduction -- Psychological Evaluation -- The Psychodiagnosis Process -- The Psychological Interview as a Methodological Resource -- Instruments for the Evaluation of Substance Use Disorders -- The Returning Interview -- Final Considerations -- References -- Chapter 13: Evidence-Based Psychotherapy for Substance Use Disorder -- Introduction -- Empirically Sustained Treatments -- Motivational Interviewing -- Motivational Enhancement Therapy -- Community Reinforcement Approach -- Contingency Management -- Behavioral Couple Therapy -- Clinical Expertise -- Patient Idiosyncrasies -- References -- Chapter 14: Substance Use Disorders and Psychiatric Multimorbidity -- Introduction -- Comorbidity and Multimorbidity -- Alcohol. Marijuana and Other Cannabinoids -- Cocaine/Crack -- Nicotine -- Final Considerations -- References -- Chapter 15: Behavioral Pharmacology: Contributions to Understanding Substance-Related and Addictive Disorders -- Introduction -- The Reflex Conditioning (The Drug as US): Functional Alternatives for Understanding Abstinence, Tolerance, and Overdose -- The Operant Conditioning (The Drug as Sd, R+ and R−): Functional Alternatives for Understanding Drug Self-Administration -- Behavioral Alternatives for Substance Dependence Intervention -- Final Considerations -- References -- Chapter 16: Disorders Due to Substance Use in Clinical Behavior Analysis: Theory and Practice Observed in a Clinical Case -- Introduction -- Analytical-Behavioral View of Substance Use Disorder -- Clinical Case -- Participant and Therapeutic Procedure -- Results -- Self-monitoring -- Functional Analysis of Alcohol Consumption -- Social Skills Training -- Background Management and Gradual Reduction -- Training of Alternative and Competing Responses for Access to Other Boosters -- Final Considerations -- References -- Chapter 17: Psychological Trauma: Biological and Psychosocial Aspects of Substance Use Disorders -- Introduction -- The Concept of Psychological Trauma -- The Relationships between Trauma and Use and Dependency on Substances: What Do the Researches Show? -- Posttraumatic Stress Disorder and Substance Use Disorders -- Exposure to Natural Disasters and the Use of Substances -- Armed Conflicts: Physical and Emotional Health Impacts and Substance Use Relationships -- Consumption of Alcohol, Tobacco, and Other Drugs Among Immigrants -- Traumas and Alcohol Use Among American Indians and Alaskan Natives -- Gender Vulnerabilities and Human Rights: Violence, Trauma, and Substance Dependence during Pregnancy and Early Motherhood. "Life at the River Is a Living Hell": The Case of Fishing Women in Zambia -- Neurobiological and Behavioral Aspects Related to Traumatic Experiences and Their Relationship to Substance Use Disorders -- Prevention of Use and Dependence and Substances and Other Disorders -- Final Considerations -- References -- Chapter 18: Motivational Interviewing in the Treatment of Substance Dependents: Clinical Fundamentals for Increased Adherence to Treatment -- Introduction -- Historical Overview -- Current Surveys -- What Is a Motivational Interviewing? -- Ambivalence -- The Motivational Interviewing Process -- Engaging -- Focusing -- Evoking -- Planning -- Essential Skills in The Motivational Interviewing -- Asking Open Questions -- Reflective Listening -- Affirmation: Positive Reinforcement -- Summary -- The Spirit of Motivational Interviewing -- Partnership -- Acceptance -- Evocation -- Compassion -- Final Considerations -- References -- Chapter 19: Assessment and Intervention in Social and Coping Skills for Alcohol and Drug Users -- Introduction -- Historical Overview and Current Researches -- Coping Skills-Based Evaluation and Intervention -- Final Considerations -- References -- Chapter 20: Psychoeducation in the Treatment of Smoking and Alcohol Use Disorder -- Introduction -- Methods and Modalities of Psychoeducation -- Psychoeducation Applied to the Treatment of Smoking and Alcohol Use Disorder -- Psychoeducation in the Treatment of Smoking -- Clinical Case -- Final Considerations -- References -- Chapter 21: Mindfulness for the Treatment of Substance Use Disorders -- Introduction -- Mindfulness in the Treatment of Substance Use Disorders -- Mindfulness Beyond Relapse Prevention -- How Mindfulness Promotes Change: Exploring Mechanisms of Action -- Mindfulness for Substance Use Disorders: A Summary of Scientific Evidence. Implementation of MBRP in Clinical Practice in CAPS-Ad and Inpatient Services. |
| Record Nr. | UNINA-9910483187003321 |
|
De Micheli Denise
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Non-medical and illicit use of psychoactive drugs / / edited by Suzanne Nielsen, Raimondo Bruno, Susan Schenk
| Non-medical and illicit use of psychoactive drugs / / edited by Suzanne Nielsen, Raimondo Bruno, Susan Schenk |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 |
| Descrizione fisica | 1 online resource (209 pages) : illustrations, tables |
| Disciplina | 615.788 |
| Collana | Current Topics in Behavioral Neurosciences |
| Soggetto topico |
Neurosciences
Experiential research Pharmacology Psychiatry Psychology Research Pharmacology/Toxicology |
| ISBN | 3-319-60016-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface -- Preclinical effects of antipsychotic drugs -- Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the development of an MDMA (“ecstasy”) Substance Use Disorder -- The Abuse Potential of Prescription Opioids in Humans – Closing in on the First Century of Research -- Over-the-Counter codeine –from therapeutic use to dependence, and the grey areas in between -- Injection of pharmaceuticals designed for oral use: Harms experienced and effective harm reduction through filtration -- Misuse of Methylphenidate -- Misuse and Associated Harms of Quetiapine, and Other Atypical Antipsychotics -- Benzodiazepines -- Recent trends in alcohol and other drug use among police detainees in New Zealand, 2010–2015 -- The Impact of Legalizing and Regulating Weed: Issues with Study Design and Emerging Findings in the U.S. |
| Record Nr. | UNINA-9910253942403321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Novel Psychoactive Substances : Policy, Economics and Drug Regulation / / edited by Ornella Corazza, Andres Roman-Urrestarazu
| Novel Psychoactive Substances : Policy, Economics and Drug Regulation / / edited by Ornella Corazza, Andres Roman-Urrestarazu |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 |
| Descrizione fisica | 1 online resource (177 pages) |
| Disciplina | 615.788 |
| Soggetto topico |
Health economics
Public health Pharmacy Health care management Health services administration Health Economics Public Health Health Care Management |
| ISBN | 3-319-60600-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1.The Global Emergence of NPS: An Analysis of a New Drug Trend -- 2.Legislating NPS in the European Union -- 3.Regulation as Global Drug Governance – How New is the NPS Phenomenon? -- 4.Anti-Doping Challenges with Novel Psychoactive Substances in Sport -- 5.Exploring Novel Policy Responses to NPS and ‘legal highs’ in New Zealand, Poland, Republic of Ireland and the United Kingdom -- 6.Regulating NPS in the Middle East: A Critical Juncture -- 7.Finding Novel Policy Response to the Challenge of NPS in Kazakhstan: Reconsidering Existing Policy and the Work of Health Professionals -- 8.NPS Policy Pitfalls: The Implementation and Management Challenges Within the Prison, Police and Health Services in the United Kingdom -- 9.NPS: An Opportunity to Move From Blanket Prohibition to a More Functionalist Approach? -- 10.The Challenges in Interpreting National-Level Strategic Indicators: A Drug Enforcement Administration Analyst’s Perspective -- 11.Harmonizing NPS Legislation Across the European Union: An Utopia? -- 12.New psychoactive substances: The Regulatory Experience and Assessment of Options. |
| Record Nr. | UNINA-9910254490203321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pocket prescriber psychiatry / / edited by Jonathan P. Rogers, Cheryl C.Y. Leung, Timothy R.J. Nicholson
| Pocket prescriber psychiatry / / edited by Jonathan P. Rogers, Cheryl C.Y. Leung, Timothy R.J. Nicholson |
| Pubbl/distr/stampa | Boca Raton : , : CRC Press, , [2020] |
| Descrizione fisica | 1 online resource (xxviii, 448 pages) : color illustrations |
| Disciplina | 615.788 |
| Collana | Gale eBooks |
| Soggetto topico |
Mental illness
Psychotropic drugs |
| Soggetto genere / forma | Handbook |
| ISBN |
1-000-09428-6
1-000-08486-8 0-429-31733-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Common/useful drugs -- Disorders -- Psychosis -- Bipolar affective disorder -- Depression -- Anxiety disorders -- Dementia -- ADHD -- Sleep disorders and agitation -- Substance abuse -- Other (non-pharmacological) therapies -- Basic psychopharmacology -- Miscellaneous -- Emergencies. |
| Record Nr. | UNINA-9910793769803321 |
| Boca Raton : , : CRC Press, , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pocket prescriber psychiatry / / edited by Jonathan P. Rogers, Cheryl C.Y. Leung, Timothy R.J. Nicholson
| Pocket prescriber psychiatry / / edited by Jonathan P. Rogers, Cheryl C.Y. Leung, Timothy R.J. Nicholson |
| Pubbl/distr/stampa | Boca Raton : , : CRC Press, , [2020] |
| Descrizione fisica | 1 online resource (xxviii, 448 pages) : color illustrations |
| Disciplina | 615.788 |
| Collana | Gale eBooks |
| Soggetto topico |
Mental illness
Psychotropic drugs |
| Soggetto genere / forma | Handbook |
| ISBN |
1-000-09428-6
1-000-08486-8 0-429-31733-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Common/useful drugs -- Disorders -- Psychosis -- Bipolar affective disorder -- Depression -- Anxiety disorders -- Dementia -- ADHD -- Sleep disorders and agitation -- Substance abuse -- Other (non-pharmacological) therapies -- Basic psychopharmacology -- Miscellaneous -- Emergencies. |
| Record Nr. | UNINA-9910821507103321 |
| Boca Raton : , : CRC Press, , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Polypharmacy in psychiatry practice . Volume 1 Multiple medication use strategies / / Michael S. Ritsner, editor
| Polypharmacy in psychiatry practice . Volume 1 Multiple medication use strategies / / Michael S. Ritsner, editor |
| Edizione | [1st ed. 2013.] |
| Pubbl/distr/stampa | Dordrecht, : Springer, 2013 |
| Descrizione fisica | 1 online resource (295 p.) |
| Disciplina |
615.7/88
615.788 616.8918 |
| Altri autori (Persone) | RitsnerMichael S |
| Soggetto topico |
Polypharmacy
Psychopharmacology |
| ISBN |
1-299-40842-7
94-007-5805-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Polypharmacy in Psychiatry Practice Volume I; About the Editor; Preface; Contents; Contributors; Part I: Polypharmacy Treatment Strategies; Chapter 1 : Multiple Psychiatric Medications Use in Psychiatry: How Rational Can It Be?; 1.1 Introduction; 1.2 Rationale for MMU in HIV; 1.3 Rationale for MMU in Cancer; 1.4 Rationale for MMU in Parkinson's Disease; 1.5 The Principles and the Rationale for MPMU; 1.5.1 Pharmacokinetic Drug Interactions; 1.5.2 Pharmacodynamic Drug Interactions; 1.5.3 Interactions Involving both Pharmacokinetic and Pharmacodynamic Mechanisms
1.6 Conclusions and Future DirectionsReferences; Chapter 2: Receptor Binding Targets for Antipsychotic Efficacy; 2.1 Introduction; 2.2 Methods; 2.2.1 Data Analysis; 2.3 Results; 2.4 Discussion; 2.4.1 D3 Dopamine Receptor Provides a Molecular Binding Target for Antipsychotic Efficacy; 2.4.2 Serotonin Receptor Contributions to Antipsychotic Efficacy; 2.5 Limitations; 2.6 Conclusions and Future Directions; References; Chapter 3: Drug Interactions and Polypharmacy; 3.1 Introduction; 3.2 Pharmacodynamic Interactions; 3.2.1 Pharmacodynamic Drug Interaction Classification 3.2.2 Time Course of Pharmacodynamic Interactions3.2.3 Serious Pharmacodynamic Interactions; 3.2.3.1 Hypertension and Hypertensive Crisis; 3.2.3.2 Serotonin Syndrome; 3.2.3.3 Bleeding; 3.2.3.4 Psychosis and Extrapyramidal Side Effects; 3.2.3.5 CNS Depression; 3.2.3.6 Anticholinergic Effects; 3.2.3.7 Arrhythmias/QTc Prolongation; 3.3 Pharmacokinetic Drug Interactions; 3.4 Clinical Effects of Drug Interactions; 3.4.1 Risk Factors; 3.5 Drug Interaction Software; 3.6 Prevention and Management of Drug Interactions; 3.7 Resources for Assessing Drug Interactions; 3.8 Conclusions Appendix. Commonly Encountered Psychotropic Interactions [ 9, 47, 59, 74 ]References; Chapter 4: Preclinical and Clinical Investigation of Antipsychotic Polypharmacy: What Is the Evidence?; 4.1 Introduction; 4.2 What Is the Preclinical Evidence for Antipsychotic Polypharmacy?; 4.3 Antipsychotic Polypharmacy in Clinical Practice; 4.3.1 Prevalence of Antipsychotic Polypharmacy; 4.3.2 Explaining the Differences in Prevalence of Antipsychotic Polypharmacy Among Studies; 4.3.3 Does the Prevalence of Polypharmacy Depend on the Baseline Antipsychotic Agent? 4.3.4 Prevalence of Polypharmacy: Change Over Time4.3.5 Predictors of Polypharmacy; 4.3.5.1 Patient Factors; 4.3.5.2 Setting and Therapists Factors; 4.3.6 Other Factors Associated with Antipsychotic Polypharmacy; 4.3.6.1 Mortality; 4.3.6.2 Increased Total Antipsychotic Dose; 4.3.6.3 Cost; 4.3.6.4 Cognitive Impairment; 4.4 Efficacy of Polypharmacy; 4.4.1 Meta-analyses; 4.4.2 Reviews; 4.4.3 Discontinuation Studies; 4.5 Management of Antipsychotic Polypharmacy; 4.6 Discussing the Evidence; 4.7 Conclusions and Future Directions; References Chapter 5: Should High Dose or Very Long-Term Antipsychotic Monotherapy Be Considered Before Antipsychotic Polypharmacy? |
| Record Nr. | UNINA-9910437844903321 |
| Dordrecht, : Springer, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
